FlowFrame is a prediction market media and analytics company. We publish original research and written analysis on Polymarket and Kalshi markets, provide real-time analytics tools for traders, and track smart money activity across prediction market platforms.

What kind of analysis does FlowFrame publish?

FlowFrame publishes deep-dive research articles that break down specific prediction market contracts. Our analysts identify mispriced markets by examining the underlying logistics, politics, and data that most traders overlook. Each piece includes a clear thesis, probability model, and actionable trade recommendation.

What analytics tools does FlowFrame offer?

FlowFrame provides real-time market dashboards, order flow analysis, whale activity tracking, a paper trading simulator, a hedge calculator, and political risk intelligence tools. These help traders monitor prediction markets, spot opportunities, and test strategies before committing capital.

What is smart money tracking?

Smart money tracking identifies large, sophisticated traders whose positions historically predict market outcomes. FlowFrame monitors wallet-level activity on Polymarket and Kalshi to surface when whales are entering or exiting positions, giving users an informational edge before prices move.

What prediction markets does FlowFrame cover?

FlowFrame covers Polymarket, the largest decentralized prediction market, and Kalshi, a CFTC-regulated prediction exchange. Coverage spans politics, economics, policy decisions, geopolitics, sports, entertainment, and corporate actions.

Is FlowFrame free to use?

Yes. FlowFrame's research articles, market dashboards, and core analytics tools are free to access. We believe prediction market intelligence should be widely available to help traders make informed decisions.

Retatrutide 2026 approval odds ease on Lilly's late-year filing timeline

February 2, 2026 · flowframe Pulse

The market dipped following reports that Eli Lilly expects to submit its regulatory filing for the triple-agonist weight-loss drug later this year. Given the standard ten-month FDA review period and ongoing Phase 3 trials, investors are increasingly pricing in a 2027 approval date rather than a 2026 window.

32¢ → 28¢ • Vol: $0.3M